<div id="readability-page-1"><p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $303.00 and last traded at $315.0280, with a volume of 26671 shares changing hands. The stock had previously closed at $268.95.</p><h2>Analysts Set New Price Targets</h2><p>A number of equities research analysts recently weighed in on PRAX shares. Oppenheimer  restated an &#34;outperform&#34; rating and set a $750.00 price objective (up from $250.00) on shares of Praxis Precision Medicines in a research note on Monday, December 15th. Deutsche Bank Aktiengesellschaft  set a $313.00 price objective on shares of Praxis Precision Medicines in a research report on Friday, December 12th. Wedbush  reissued an &#34;underperform&#34; rating and set a $83.00 target price (up previously from $77.00) on shares of Praxis Precision Medicines in a research report on Friday, December 5th. Needham &amp; Company LLC raised their target price on shares of Praxis Precision Medicines from $304.00 to $315.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, December 8th. Finally, HC Wainwright  reaffirmed a &#34;buy&#34; rating and set a $340.00 price target (up from $258.00) on shares of Praxis Precision Medicines in a research report on Friday, December 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued  a Buy rating and two have assigned  a Sell rating to the stock. Based on data from MarketBeat.com, Praxis Precision Medicines  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $426.20.</p><p><b>Check Out Our Latest Stock Report on Praxis Precision Medicines</b></p><h2>Praxis Precision Medicines Trading Up 15.8%</h2><p>The business's 50-day simple moving average is $210.93 and its 200-day simple moving average is $107.38. The company has a market capitalization of $7.79 billion, a PE ratio of -23.87 and a beta of 2.95. </p><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.45) by $0.09.  Sell-side analysts forecast that  Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year. </p><h2>Insider Activity</h2><p>In related news, insider Lauren Mastrocola sold 13,600 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total value of $2,612,288.00. Following the completion of the sale, the insider owned 10,442 shares of the company's stock, valued at approximately $2,005,699.36. The trade was a 56.57% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the sale, the general counsel owned 20,832 shares in the company, valued at approximately $4,022,450.88. This trade represents a 54.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own  2.70% of the company's stock. </p><h2>Institutional Investors Weigh In On Praxis Precision Medicines</h2><p>Institutional investors have recently made changes to their positions in the stock. Nuveen LLC purchased a new position in  Praxis Precision Medicines in the 1st quarter valued at approximately $559,000.  Adage Capital Partners GP L.L.C. increased its stake in shares of  Praxis Precision Medicines by 188.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company's stock worth $65,998,000 after acquiring an additional 1,137,748 shares during the period.  Ally Bridge Group NY LLC boosted its holdings in  Praxis Precision Medicines by 112.5% in the 1st quarter. Ally Bridge Group NY LLC now owns 95,582 shares of the company's stock valued at $3,620,000 after purchasing an additional 50,600 shares in the last quarter.  Cormorant Asset Management LP raised its stake in shares of  Praxis Precision Medicines by 3.1% during the 1st quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company's stock worth $66,083,000 after buying an additional 51,781 shares in the last quarter.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in  Praxis Precision Medicines by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares of the company's stock worth $444,000 after acquiring an additional 573 shares during the period. 67.84% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Praxis Precision Medicines Company Profile</h2> (Get Free Report)<p>Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.  </p><p>The company's pipeline includes several lead candidates at various stages of development.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Praxis Precision Medicines</li><li>Do not delete, read immediately</li><li>How the Rich Retire</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>How Long Will $1M Last in Retirement?</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

PRAX

<p>Praxis Precision Medicines (NASDAQ:PRAX) reached a new 52-week high of $315.03, up from a previous close of $268.95. Analysts have set varied price targets, with Oppenheimer raising its target to $750.00. The stock has a consensus rating of "Moderate Buy" and an average target price of $426.20. The company reported an EPS of ($3.36), beating estimates. Insider trading activity includes significant sales by executives. Institutional investors hold 67.84% of the stock, indicating strong institutional interest.</p>

Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High - Time to Buy?